Gapping up
In reaction to strong earnings/guidance: AVH +3.3%
M&A news:
In reaction to strong earnings/guidance: AVH +3.3%
M&A news:
- MDVN +19.7% (confirms deal to be acquired by Pfizer (PFE) for $81.50/share in cash, or ~$14 bln)
- SYT +10.7% (Syngenta and ChemChina confirm regulatory clearance for M&A deal from Committee on Foreign Investment in the United States)
- SSY +9.9% (subsidiary sells Chestatee Regional Hospital in Dahlonega, Georgia for ~$15 mln)
Other news:
- BPMX +34.6% (announces final phase 2a trial results; BPX-01 reduces facial P. acnes by more than 90% in four weeks)
- CYCC +16.2% (Tang Capital discloses 9.6% passive stake)
- RLJE +14.3% (enters into investment agreement with Digital Entertainment Holdings LLC, a wholly owned subsidiary of AMC Networks (AMCX))
- VRX +3.4% (confirms former Zoetis (ZTS) CFO Paul Herendeen will replace Robert Rosiello as CFO effective immediately)
- BMRN +3.3% (in sympathy with MDVN), GEO +2.4% (slightly rebounding following last week's 29% decline)
- CXW +2.2% (slightly rebounding following last week's 30% decline)
- FMS +1.8% (issues statement regarding Centers for Medicare & Medicaid Services request for information)
- MON +1.2% (in sympathy with SYT)
Analyst comments:
- VNCE +6.6% (upgraded to Overweight from Neutral at Piper Jaffray)
- CSII +1.8% (upgraded to Outperform from Mkt Perform at Leerink Partners)
- LB +1.2% (upgraded to Buy from Neutral at Goldman)
- HRL +0.9% (upgraded to Outperform from Neutral at Credit Suisse)